This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
The Tα1 group had a 90-day liver transplantation-free survival rate of 75.0% compared to 53.4% in the SMT group.
Why it matters
These findings suggest that Tα1 could be a valuable treatment option for improving outcomes in patients with severe liver failure due to hepatitis B. Reducing infection rates is crucial for enhancing patient survival.
How the study worked
This was an open-label, randomized controlled trial involving 120 patients with HBV-related acute-on-chronic liver failure.
What this study cannot tell us
The study was open-label and may have biases; further research is needed to confirm long-term effects and benefits in diverse populations.
Read the original research
Safety and efficacy of Thymosin α1 in the treatment of hepatitis B virus-related acute-on-chronic liver failure: a randomized controlled trial.
Hepatology international, 16(4), 775-788
Citation
Chen, Jun-Feng; Chen, Shu-Ru; Lei, Zi-Ying; Cao, Hui-Juan; Zhang, Shao-Quan; Weng, Wei-Zhen; Xiong, Jing; Lin, Deng-Na; Zhang, Jing; Zheng, Yu-Bao; Gao, Zhi-Liang; Lin, Bing-Liang. (2022). Safety and efficacy of Thymosin α1 in the treatment of hepatitis B virus-related acute-on-chronic liver failure: a randomized controlled trial.. Hepatology international, 16(4), 775-788. https://doi.org/10.1007/s12072-022-10335-6